Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers.[1] It also acts as a β3 receptor agonist.[2] A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[3]
Clinical data | |
---|---|
Trade names | Almarl |
Other names | S-596 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 2 hours |
Elimination half-life | 10 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C15H21N3O2S3 |
Molar mass | 371.53 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It is used in the treatment of high blood pressure[4] and essential tremor.[5][6] Recommended dosage is 10 to 30 mg per day.[citation needed]